Review



qggp  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress qggp
    IQGAP1 inhibitor <t>QGGP</t> enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h <t>after</t> <t>DTX</t> treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).
    Qggp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n7024/Quercetin+3-O-(6''-galloyl)-%CE%B2-D-galactopyranoside/pmc12789717-174-41-46
    Average 93 stars, based on 1 article reviews
    qggp - by Bioz Stars, 2026-10
    93/100 stars

    Images

    1) Product Images from "Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer"

    Article Title: Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer

    Journal: Journal of Advanced Research

    doi: 10.1016/j.jare.2024.12.003

    IQGAP1 inhibitor QGGP enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h after DTX treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).
    Figure Legend Snippet: IQGAP1 inhibitor QGGP enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h after DTX treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Techniques Used: Western Blot, Expressing, Binding Assay, Drug discovery, Thermal Shift Assay, Control, Recombinant

    Related Articles

    Control:

    Article Title: Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer
    Article Snippet: .. To investigate the impact of CAFs on DTX treatment, the mice were treated every three days with either a control solution (composed of 10% DMSO, 40% PEG300, 5% Tween80, and 45% ddH2O, administered intraperitoneally), DTX (5 mg/kg, intraperitoneally, from Selleck, S1148), QGGP (5 mg/kg, intraperitoneally, from MedChemExpress, HY-N7024), or a combination of DTX and QGGP. ..

    Article Title: Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer.
    Article Snippet: .. To investigate the impact of CAFs on DTX treatment, the mice were treated every three days with either a control solution (composed of 10% DMSO, 40% PEG300, 5% Tween80, and 45% ddH2O, administered intraperitoneally), DTX (5 mg/kg, intraperitoneally, from Selleck, S1148), QGGP (5 mg/kg, intraperitoneally, from MedChemExpress, HY-N7024), or a combination of DTX and QGGP. ..



    Similar Products

    qggp  (MedChemExpress)
    93
    MedChemExpress qggp
    IQGAP1 inhibitor <t>QGGP</t> enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h <t>after</t> <t>DTX</t> treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).
    Qggp, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n7024/Quercetin+3-O-(6''-galloyl)-%CE%B2-D-galactopyranoside/pmc12789717-174-41-46
    Average 93 stars, based on 1 article reviews
    qggp - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    quercetin 3-o-(6''-galloyl)-β-d-galactopyranoside  (MedChemExpress)
    93
    MedChemExpress quercetin 3-o-(6''-galloyl)-β-d-galactopyranoside
    IQGAP1 inhibitor <t>QGGP</t> enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h <t>after</t> <t>DTX</t> treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).
    Quercetin 3 O (6'' Galloyl) β D Galactopyranoside, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n7024/Quercetin+3-O-(6''-galloyl)-%CE%B2-D-galactopyranoside/custom%40hy-n7024%4039647634
    Average 93 stars, based on 1 article reviews
    quercetin 3-o-(6''-galloyl)-β-d-galactopyranoside - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    IQGAP1 inhibitor QGGP enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h after DTX treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Journal: Journal of Advanced Research

    Article Title: Cancer-associated fibroblasts regulate mitochondrial metabolism and inhibit chemosensitivity via ANGPTL4-IQGAP1 axis in prostate cancer

    doi: 10.1016/j.jare.2024.12.003

    Figure Lengend Snippet: IQGAP1 inhibitor QGGP enhances the chemosensitivity of PCa. A. Workflow of HTVS for IQGAP1 inhibitor identification. B. Western blot analysis of IQGAP1 expression in PCa cells treated by the top three inhibitors showing the strongest binding ability in the FDA-Approved Drug Library and MCE Bioactive Compound Library for 24 h. C. The chemical structure and molecular docking model of the binding between QGGP and the human IQGAP1 protein. QGGP forms seven hydrogen bonds with IQGAP1: the five phenolic hydroxyl groups can form five hydrogen bonds with ASP1488, LEU1290, TYR977, THR1289, and THR1291, and the two hydroxyl groups on the sugar ring can form two hydrogen bonds with ASN1387. D. E. Cellular thermal shift assay was used to determine the effect of QGGP on IQGAP1 protein stability (n = 3). F. G. Apoptosis analysis of PCa cells with indicated treatments. PCa cells were pretreated with QGGP (10 μM) or DMSO for 1 h, followed by control medium or recombinant ANGPTL4 (3 ug/ml). Apoptosis analyses were performed 24 h after DTX treatment (n = 3). H. The volume of tumors in the indicated groups, measured every 3 days (n = 3). I. J. Representative images and sizes of subcutaneous tumors formed by human 22RV1 cells co-transplanted with or without CAFs into BALB/C-nude mice and treated with control, DTX, QGGP, or combination (n = 3). K. The body weight in the indicated groups, measured every 3 days (n = 3). (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001).

    Article Snippet: To investigate the impact of CAFs on DTX treatment, the mice were treated every three days with either a control solution (composed of 10% DMSO, 40% PEG300, 5% Tween80, and 45% ddH2O, administered intraperitoneally), DTX (5 mg/kg, intraperitoneally, from Selleck, S1148), QGGP (5 mg/kg, intraperitoneally, from MedChemExpress, HY-N7024), or a combination of DTX and QGGP.

    Techniques: Western Blot, Expressing, Binding Assay, Drug discovery, Thermal Shift Assay, Control, Recombinant